3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Leukemia, Prolymphocytic, B-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Myeloid, Acute
2
Study of Risk Factors for IPMNs Degeneration at the Nancy CHRU
1
Stomach Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Leukemia, Prolymphocytic, T-Cell
1
Leukemia, Myeloid
1
Leukemia, Large Granular Lymphocytic
1
Immunoblastic Lymphadenopathy
1
Enteropathy-Associated T-Cell Lymphoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Dexamethasone
64
Cyclophosphamide
40
Bortezomib
37
Melphalan
24
Lenalidomide
23
Thalidomide
17
pomalidomide
16
fludarabine
12
daratumumab
11
carfilzomib
10
Filgrastim
8
Doxorubicin
8
Busulfan
6
Prednisone
5
Peripheral Blood Stem Cell Transplantation
5
Bendamustine Hydrochloride
5
selinexor
4
sargramostim
4
isatuximab
4
fludarabine phosphate
4
Surveys and Questionnaires
4
Etoposide
4
Clarithromycin
4
Calcium Dobesilate
4
liposomal doxorubicin
3
ixazomib
3
Radiotherapy
3
Neoadjuvant Therapy
3
Mycophenolic Acid
3
Methylprednisolone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Multiple Myeloma
×
Sensitivity and Specificity
×
Clear all
NCT01886976
2016-01-28
CART-138
Chinese PLA General Hospital
Phase 1/2
Unknown
10 enrolled